Literature DB >> 23614654

Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century.

Nauman S Chaudhry1, Ashish H Shah, Nicholas Ferraro, Brian M Snelling, Amade Bregy, Karthik Madhavan, Ricardo J Komotar.   

Abstract

Over the last quarter century there has been significant progress toward identifying certain characteristics and patterns in GBM patients to predict survival times and outcomes. We sought to identify clinical predictors of survival in GBM patients from the past 24 years. We examined patient survival related to tumor locations, surgical treatment, postoperative course, radiotherapy, chemotherapy, patient age, GBM recurrence, imaging characteristics, serum, and molecular markers. We present predictors that may increase, decrease, or play no significant role in determining a GBM patient's long-term survival or affect the quality of life.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614654     DOI: 10.3109/07357907.2013.789899

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  27 in total

1.  Distance-based classifiers as potential diagnostic and prediction tools for human diseases.

Authors:  Boris Veytsman; Lei Wang; Tiange Cui; Sergey Bruskin; Ancha Baranova
Journal:  BMC Genomics       Date:  2014-12-19       Impact factor: 3.969

2.  Prediction of glioma recurrence using dynamic ¹⁸F-fluoroethyltyrosine PET.

Authors:  T Pyka; J Gempt; F Ringel; S Hüttinger; S van Marwick; S Nekolla; H-J Wester; M Schwaiger; S Förster
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-12       Impact factor: 3.825

3.  MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme.

Authors:  Michael Henriksen; Kasper Bendix Johnsen; Pia Olesen; Linda Pilgaard; Meg Duroux
Journal:  Neuromolecular Med       Date:  2014-05-10       Impact factor: 3.843

4.  Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.

Authors:  Alessandro Della Puppa; Giuseppe Lombardi; Marta Rossetto; Oriela Rustemi; Franco Berti; Diego Cecchin; Marina Paola Gardiman; Giuseppe Rolma; Luca Persano; Vittorina Zagonel; Renato Scienza
Journal:  J Neurooncol       Date:  2016-10-18       Impact factor: 4.130

5.  Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.

Authors:  Thomas Pyka; Jens Gempt; Daniela Hiob; Florian Ringel; Jürgen Schlegel; Stefanie Bette; Hans-Jürgen Wester; Bernhard Meyer; Stefan Förster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-29       Impact factor: 9.236

6.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

7.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Authors:  Remco J Molenaar; Dagmar Verbaan; Simona Lamba; Carlo Zanon; Judith W M Jeuken; Sandra H E Boots-Sprenger; Pieter Wesseling; Theo J M Hulsebos; Dirk Troost; Angela A van Tilborg; Sieger Leenstra; W Peter Vandertop; Alberto Bardelli; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Neuro Oncol       Date:  2014-02-06       Impact factor: 12.300

8.  Magnetic Resonance Imaging Parameters and Their Impact on Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival.

Authors:  Bob L Hou; Sijin Wen; Gennadiy A Katsevman; Hui Liu; Ogaga Urhie; Ryan C Turner; Jeffrey Carpenter; Sanjay Bhatia
Journal:  World Neurosurg       Date:  2018-12-27       Impact factor: 2.104

9.  A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.

Authors:  Ashish H Shah; Robert Suter; Pavan Gudoor; Tara T Doucet-O'Hare; Vasileios Stathias; Iahn Cajigas; Macarena de la Fuente; Vaidya Govindarajan; Alexis A Morell; Daniel G Eichberg; Evan Luther; Victor M Lu; John Heiss; Ricardo J Komotar; Michael E Ivan; Stephan Schurer; Mark R Gilbert; Nagi G Ayad
Journal:  Neurooncol Adv       Date:  2021-12-31

10.  Community economic factors influence outcomes for patients with primary malignant glioma.

Authors:  Aaron Bower; Fang-Chi Hsu; Kathryn E Weaver; Caleb Yelton; Rebecca Merrill; Robert Wicks; Mike Soike; Angelica Hutchinson; Emory McTyre; Adrian Laxton; Stephen Tatter; Christina Cramer; Michael Chan; Glenn Lesser; Roy E Strowd
Journal:  Neurooncol Pract       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.